North Sea, a Dutch drug company, completed a $40 million financing

in recent years, despite some progress in the development of non-alcoholic fatty hepatitis treatment drugs, clinical development still faces many challenges, and researchers have been struggling with the efficacy and safety of the drugs they are working on. This has led to the emergence of no approved treatment for the disease.At the end of 2017, North Sea Therapeutics, a Dutch biopharmaceutical company, announced the completion of a $25 million round of A-round financing, making it the focus of industry attention. Today, it again announced the completion of a $40 million round B financing, which will be used primarily for its first-of-its-kind oral design structure fatty acid (SEFA) drug icosabutate to treat patients with non-alcoholic fatty hepatitis (NASH) in Phase 2b clinical studies in ICONA.NASH is a serious aggressive liver disease. Patients with excessive accumulation of fat in the liver stimulate chronic inflammation, leading to aggressive liver fibrosis. This can eventually lead to cirrhosis, liver failure, liver cancer and death. There are currently no approved treatments for the disease.NorthSea's icosabutate is a design-enhanced omega-3 fatty acid molecule that is structurally improved compared to traditional prescription omega-3 fatty acids, with the aim of improving its effects in reducing triglycerides (TGs), improving drug llerment and drug preservation safety. Two previous Phase 2 clinical studies have shown that icosabutate is a safe and effective drug for the treatment of high triglycerideemia. NorthSea said it had completed the trial's first patient in September and expected it to be completed by 2021.In addition, the money will be used for the development of two other omega-3 compounds under North Sea research. One of them is SEFA-1024, which is used to treat blood lipid abnormalities. Severe or untreated blood lipid abnormalities can lead to a variety of health conditions, including coronary artery disease and peripheral artery obstruction disorders. The company plans to launch phase 1 clinical studies of SEFA-1024 in the second half of 2020. Another compound in studying omega-3 is SEFA-6179, which is used to treat patients with intestinal nutrition-related liver disease (PNALD). PNALD is a rare liver disease that affects patients with bowel failure who rely on alternative routes to nutrition delivery through the oral or gastrointestinal system. Currently, there are no approved treatments for the disease. NorthSea expects to launch phase 1 clinical studies of SEFA-6179 in the first half of 2021.“ In our blood lipid studies of more than 200 patients, we found that icosabutate is very safe. This suggests that iosabutate can reduce patients' cholesterol while reducing triglycerides," said Rob de Ree, CHIEF Executive Officer of NorthSea. "we also expect icosabutate to affect the lives of millions of NASH patients around the world. (Creating a foreign exchange)